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Background: Severe knee pain associated with osteoarthritis (OA) is one of the most common and troublesome
symptoms in the elderly. Recently, local bone denervation by MR-guided focused ultrasound (MRgFUS) has been
demonstrated as a promising tool for pain palliation of bone metastases. The purpose of this study was to develop
a novel treatment for knee OA using MRgFUS, and to validate its safety and efficacy.
Methods: Eight patients with medial knee pain and eligible for total knee arthroplasty were included. MR-guided
focused sonication treatments were applied to bone surface just below the rim osteophyte of medial tibia plateau
with real-time monitoring of the temperature in the target sites. The pain intensity during walking was assessed on
a 100 mm visual analog scale (VAS) before and after treatment. Pressure pain thresholds (PPTs) were also evaluated
over several test sites adjacent to the sonication area and control sites one month after treatment.
Results: Six patients (75%) showed immediate pain alleviation after treatment, and four of them demonstrated
long-lasting effect at 6-month follow up (mean VAS reduction; 72.6%). In responders, PPTs in medial knee were
significantly increased after treatment (Median; pre- 358 kpa vs post- 534 kpa, p < 0.0001). There were no adverse
side effects or complications during and after treatment.
Conclusions: These initial results illustrate the safety and efficacy of the newly developing MRgFUS treatment.
Significant increase of PPTs on treated area showed successful denervation effect on the nociceptive nerve
terminals. MRgFUS is a promising and innovative procedure for noninvasive pain management of knee OA.
Trial registration: Trial Registration: UMIN000010193
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Knee Osteoarthritis (OA) ranks among the most com-
mon disabling arthritic conditions in the elderly [1]. A
major symptom of knee OA is chronic knee pain which
has a significant effect on patients’ quality of life [2].
There are several conservative options for pain manage-
ment, including physical therapy, use of non-steroidal
anti-inflammatory drugs, intraarticular injection with
steroids or hyaluronic acids [3]. However, these treat-
ments are not sufficient to control severe knee OA pain* Correspondence: ikeuchim@kochi-u.ac.jp
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reproduction in any medium, provided the or[4]. Although total knee arthroplasty (TKA) is a vali-
dated and reliable intervention for alleviating severe
knee pain [5], there are some patients who are at high
risk during surgery and other patients who are not will-
ing to undergo surgery. The number of these patients is
expected to increase because of population aging, there-
fore, it is necessary to explore additional nonsurgical
treatments for knee OA to achieve better pain relief.
MR-guided focused ultrasound (MRgFUS) treatment is
a noninvasive technique that enables to perform local-
ized thermal ablation by focusing the acoustic energy
precisely to the targeted sites [6]. Three-dimensional
treatment planning and continuous real-time monitoring
of the temperature in the target sites by MR imaging aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the feasibility and effectiveness of MRgFUS have been
evaluated in several benign and malignant tumors such
as uterine fibroids [8,9], breast cancer [10,11], and brain
tumors [12]. In recent years, palliative therapy of bone
pain due to metastasis has been recognized as a promis-
ing alternative treatment with the mechanism of local
bone denervation [13-15]. As for a treatment of chronic
musculoskeletal pain, however, there was only one case-
series of MRgFUS application to osteoarthritic lumbar
facet joints, which targeted periosteum around facet
joint to achieve local bone denervation and reported safe
and effective outcomes against low back pain [16]. In
knee OA, tenderness of the bony margins of the joint is
a quite common symptom involved in American College
of Rheumatology criteria for clinical diagnosis [17],
which might be caused by rich nociceptive nerve termi-
nals in this area. Therefore, it is reasonable to assume
that the same mechanism as facet joint treatment is cer-
tainly available to alleviate joint pain caused by knee
OA. The purpose of this study was to develop a novel
treatment for knee OA using MRgFUS, and to validate
its safety and efficacy in an initial case series.
Methods
Patients
This case series study was carried out with the approval
of the Institutional Review Board and in a prospective,
non-controlled manner. All patients were informed
about the intervention prior to treatment, and written
consent for participation and publication of individual
clinical details were obtained. Participation was volun-
tary and did not preclude other treatment options. The
study and all interventions were carried out in the De-
partment of Orthopaedic Surgery in Kochi university
hospital between December 2010 and April 2012. Pa-
tients complaining severe medial knee pain associated
with radiological OA were recruited for this study. Inclu-
sion criteria were age older than 60 years, previous con-
servative treatments longer than 3 months, and pain
scores on an visual analog scale (VAS, 100 mm) greater
than 40 mm during walking. Radiological inclusion was
restricted to grade 4 medial knee OA according to
Kellgren-Lawrence classification [18], because the pa-
tients could be salvaged by TKA conversion. Exclusion
criteria were contraindications for MRI, psychiatric con-
ditions, and allergies of local anesthetics.
In this series, eight patients (6 female, 2 male) with the
mean age of 78 (± 6.4; standard deviation) years were
treated. The mean clinical score (Japanese Orthopedic
Association score for knee OA) was 48 (± 5.3) points
(maximum 100 points: domains are pain on walking or
stair stepping, range of motion, and joint effusion). All
patients were eligible for TKA, and half of them werescheduled surgery and underwent MRgFUS treatment
during waiting period. The others were scheduled only
for MRgFUS treatment because they were not willing to
undergo surgery.
MR-guided focused ultrasound procedures
The treatment was conducted as an outpatient setting,
using the MRgFUS system (ExAblate® 2100, InSightec
Ltd, Haifa, Israel) integrated with an MRI scanner (GE
Signa EXCITE 3.0 T MRI, Milwaukee, WI, USA). In this
series, the criteria of sonication area was determined as
the bone surface just below the rim osteophyte of medial
tibia plateau, which is the insertion site of deep medial
collateral ligament. Patients underwent local anesthesia
with 15 ml of 0.75% ropivacaine around the periosteum
in treatment sites and lay supine on the MRI table. A
conformal sonication device was strapped onto the med-
ial knee (Figure 1). This is a newly developed transducer
and chilled water is circulated within a semi-permeable
membrane to provide acoustic coupling and cool the
skin during treatment. Coronal, sagittal, and axial
unenhanced T2-weighted MR images were obtained and
loaded into MRgFUS workstation to allow accurate
three-dimensional planning and targeting of the lesion.
The outline of bone surface as well as skin and the area
to be treated were carefully drawn on the planning im-
ages of coronal and axial view. The system automatically
generated the optimal treatment plan including energy
levels and number of sonications (Figure 2). The ultra-
sound beam was angled to avoid popliteal neurovascular
bundles. Initially, a low energy test sonication was
performed to ensure safety and accuracy of the proced-
ure. Then, therapeutic sonications began with higher en-
ergy to achieve ablation. Throughout the treatment, the
location of each sonication and the temperature eleva-
tion in the tissue adjacent to the target area were moni-
tored in real time (Figure 3). The temperature elevation
was aimed at 60°C, and treatment parameters such as
energy, sonication duration or spot size were modified
in response to the monitoring. The patients held a stop
switch and were able to interrupt anytime during the
treatment.
Outcome measures
The primary outcome measure was VAS scores during
walking on a scale graduated from 0 (no pain) to
100 mm (maximal pain). A response to treatment was
defined as a 50% or greater decrease in the pain VAS
according to a proposal of Outcome Measures in
Rheumatology Clinical Trials and Osteoarthritis Re-
search Society International [19]. The VAS was collected
before, 3 days, 10 days, and 1 month after the MRgFUS
in all patients and in some patients additional VAS
scores were obtained at 3, 6, 12, and 18 months.
Figure 1 System set up. (a) Conformal sonication devise (b) Strapped onto the medial knee. Chilled water is circulated within a semi-
permeable membrane. (c) Full view of the patient.
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sured over 6 test sites adjacent to the sonication area
and at 2 control sites. The test sites in medial knee were;
A: anterior joint space; B: middle joint space; C: poster-
ior joint space; D: anterior tibia plateau; E: middle tibia
plateau; F: posterior tibia plateau. All sites were easily
identified based on the location of joint space, medial
collateral ligament and tibial osteophyte. As control
sites, lateral joint space and ipsilateral upper arm (3 cm
proximal to the humerus insertion of deltoid muscle)
were examined. A handheld algometer (Commander, JFigure 2 Three-dimensional treatment planning. Sonication site and ul
automatically generated the optimal treatment plan including energy levelTech Medical Industries, Heber city, UT, USA) with a
1 cm2 probe was used to record PPTs. The PPT was de-
fined as the first point at which patients perceived the
pressure as slight pain. PPTs were measured by single
examiner (MI) at pre- and one month post-treatment.
Prior to the pre-treatment assessment, high intra-rater
reliability was confirmed in each patient. PPTs were
recorded two times on each site and the mean threshold
was used for statistical analysis.
Radiological assessments were performed at 3 days,
1 month, 6 months and 12 months by X-ray, at 3 monthstrasound beam pathway are indicated by the examiner. The system
s and number of sonications.
Figure 3 Real-time monitoring. Current sonication spot (green circle) and ultrasound beam pathway are shown in Coronal view (a) and axial
view (b). Temperature elevation is monitored by two curves indicated mean (green) and maximum (red) temperature in the spot (c).
Figure 4 VAS scores of the pain intensity during walking at
each follow-up time point. Six patients (Case 1, 2, 4, 5, 6 and 7)
showed good pain relief after treatment.
Izumi et al. BMC Musculoskeletal Disorders 2013, 14:267 Page 4 of 8
http://www.biomedcentral.com/1471-2474/14/267by routine plain MRI of the knee. The treated bone sam-
ple was taken from patients who underwent TKA after
MRgFUS treatment and histopathological evaluation was
performed using hematoxylin and eosin staining.
Statistical analysis
The PPT data are presented as median and interquartile
range in text and figures. Kruskal-Wallis test followed by
Dunn’s test was used to compare PPTs among eight sites
at pre-treatment. Wilcoxon signed rank test was used for
comparison of difference between pre- and post-treatment
PPTs in medial knee (including 6 sites; A-F) and on each
site. Significant difference was set at p < 0.05.
Results
The mean time used for preparing the system was 86 mi-
nutes (50–120 min) while the mean treatment time was
74 minutes (50–120 min). The mean therapeutic energy
level was 735 Joules (491–952) and the mean number of
sonication was 12.4 (10–20) per patient. The mean
follow-up period was 9 (6–18) months after treatment.
There were no adverse side effects or complications
reported during and after treatment.
Pain intensity effects
The VAS scores were reduced 3 days, 10 days, and one
month compared with pre-treatment in the 6 responders
(Figure 4). In particular, four patients (Case 1, 4, 5, and
6) had long-lasting pain alleviation (mean VAS reduction
at 6 months: 72.6%). One patient (Case 7) showed recur-
rence of pain at 6-month follow up. Two patients (Case
2 and 3) underwent total knee arthroplasty one month
after MRgFUS treatment. One of the non-responders
(Case 8) dropped out and switched to opioid therapy
one month after MRgFUS treatment.
Pressure pain sensitivity
At pre-treatment and compared with the arm, the mid-
dle and posterior tibia plateau as well as posterior joint
space showed significant lower PPTs (P < 0.05; Figure 5).
In the 6 responders, the PPTs in medial knee were358 kpa [290 - 431]at pre-treatment and 534 kpa [461 -
605]at post-treatment, which showed significant difference
(p < 0.0001). In site-specific evaluation, the PPTs on mid-
dle, posterior joint space and tibia plateau were signifi-
cantly increased after treatment (P < 0.05; Figure 5),
suggesting that the nociceptive nerve terminals in the
medial knee were successfully treated. In the two non-
responders, the PPT values post-treatment were compar-
able with the pre-treatment values.
Histopahological evaluation
The cortical bone sample of the treated area was taken
from 2 patients during TKA. Light microscopic assess-
ment showed maintained bone morphology (Figure 6a)
and normal osteocytes (Figure 6b), which demonstrated
no significant focal bone necrosis due to MRgFUS
treatment.
Case
A-82 year-old woman (Case 1) underwent MRgFUS
treatment for her left knee. She had successfully
Figure 5 PPTs at pre- and post-treatment. White bar indicates pre- treatment PPTs (n = 8). Gray and black bar indicate post-treatment PPTs of
responder (n = 6) and non-responder (n = 2), respectively. # : p < 0.05 compared with Arm at pre-treatment. *: p < 0.05 compared with pre-
treatment in responders. Sonications were applied to the site D, E, F.
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been scheduled surgery for her left knee. She had medial
knee pain with the VAS of 78 mm and tenderness on
her medial joint space and tibia plateau (pre-treatment
median PPT values in the medial knee: 280 kPa). After
treatment, she reported dramatic and long-lasting reduc-
tion in her left knee pain with PPTs increase (post-treat-
ment median PPT values: 456 kPa). The clinical score
was improved from 50 points in pre- to 75 points in
post-treatment. At the 18-month follow-up, she was no
longer suffering from severe knee pain in her daily life,
and canceled her surgery. Figure 7 showed the radio-
logical changes in this patient. MRI showed a low inten-
sity curved line at the sonication site in T1 and T2
weighted images. In X-ray films, an osteoscleroticFigure 6 Histology of the bone sample in the treated area. (a) low ma
was observed. Scale bar: 50 μm.change was seen in accordance with the low intensity
curved line in MRI. There were no findings of OA pro-
gression, osteonecrotic change, or segmental collapse of
tibia plateau during follow-up period. The other patients
also showed similar courses of radiographic change after
treatment.
Discussion
This is the first report of clinical application of MRgFUS
for knee OA. Real-time monitoring of the sonication
area and temperature elevation enabled performance of
safe and accurate treatment. Even though the inclusion
was restricted to most severe OA in this pilot study, 75%
of patients showed successful pain relief. Similar to pre-
vious reports of bone metastases [13-15] or lumbar facetgnification, (b) high magnification. No significant focal bone necrosis
Figure 7 Radiological changes between treatments. (a) MRI (pre-, T2WI), (b) MRI (3 months post-, T2WI), (c) MRI (3 months post-, T1WI), (d) X-
p (pre-), (e) X-p (6 months post-), (f) X-p (12 months post-). Arrow heads in MRI indicate low intensity curved line at the sonication site. Arrows in
X-p indicate osteosclerotic change in accordance with the line in MRI.
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Unlike a conventional transducer integrated with MRI
table, a newly developed conformal sonication device
was a good fit for extremities and enabled easier treat-
ment of knee OA. Intravenous sedation and opioid ad-
ministration were not necessary for our treatment,
which were applied in the previous series of bone metas-
tases [13-15] or low back pain [16]. Local anesthesia
with ropivacaine around the periosteum was enough to
reduce pain associated with sonication. Patients were
able to relax throughout the procedure and to walk soon
after treatment.
The mechanism of pain alleviation is most likely local
denervation caused by the heat denaturation of the
treated area. However, no previous studies have sug-
gested an assessment method to estimate the denervated
area of MRgFUS. In this regard, pressure algometry is a
quite simple and useful tool for quantitative evaluation
after denervation treatment. Reliable repeated PPT mea-
surements around knee joint have been documented by
means of locating the assessment sites in relation to
bone landmark [20]. In the present study, all sites in
medial knee were easily identified based on the location
of joint space, medial collateral ligament and tibial
osteophyte, enabling to retest PPTs in a reproducible
manner. In our patients who responded to the treatment
with pain reduction, PPTs on sonication area were sig-
nificantly increased after treatment, which means that
patients felt less pain by pressure stimulation after de-
nervation. The patients who did not respond to thetreatment did not show increased pressure pain thresh-
olds which may suggest that an PPT increase would be a
necessary condition of successful treatment. Future stud-
ies will be needed to verify if earlier follow-up assess-
ments may be used to predict treatment success.
In this series, all sonications were applied to bone sur-
face just below the rim osteophyte of medial tibia plat-
eau. From a pathophysiological perspective it has been
reported that sensory nerve invasion containing sub-
stance P and calcitonin gene related peptide was seen in
tibial osteophyte in human OA patients [21]. Because
surface area of the tibial rim osteophyte itself was a bit
narrow to plan sonication, the base of the osteophyte
was treated instead. Furthermore, lower PPTs were ob-
served in this area at pre-treatment in all patients and
this is also a general finding in OA knees [17]. In other
words, hypersensitivity of nociceptive nerve terminals
against pressure stimulation was seen in this area, which
was preferable for denervation treatment. From a prac-
tical perspective there were other reasons to select the
treated area. Firstly, bone is a better indication for
MRgFUS than soft tissues. Lower thermal conductivity
and higher ultrasound absorption rate of cortical bone al-
lows the denervation treatment safe and efficient, which
had been demonstrated in previous reports [13-16]. Sec-
ondly, tibial rim osteophyte was a good landmark for re-
producible planning, treatment and assessment.
The osteosclerotic change after the treatment was in-
teresting. In our patients, the temperature elevation of
bone surface was aimed at 60°C because protein
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for a few seconds [22,23]. The goal temperature was al-
most same as previous publications, and some authors
found similar new bone formation after the treatment of
bone metastases [13,14]. The mechanism of osteosclerotic
change in the treated area is unknown. Although it cannot
be excluded that minor thermal or non-thermal bone
damage occurred, new bone formation might be an en-
couraging radiological finding of this therapy [24]. Includ-
ing its relation to the long-lasting pain relief, further basic
research of treated bone marrow would be necessary to
assess this phenomenon.
According to the pain alleviation mechanism and re-
sults of this study, a good candidate for MRgFUS treat-
ment is patient presenting with localized medial pain,
lower PPTs around tibial osteophyte, and no bone mar-
row lesion or osteonecrosis. In this series, two patients
did not respond the treatment. One patient complained
spreading medial knee pain and the other had small
bone marrow lesion in medial femoral condyle and tibia
plateau. Detailed assessment of pain distribution, pres-
sure pain sensitivity, and MRI examination before the
treatment might be essential to achieve satisfactory
results.
Percutaneous radiofrequency treatment has been
reported as a beneficial local denervation therapy for
knee OA [4,25]. Comparing with radiofrequency,
MRgFUS treatment has some advantages. Closed-loop,
real-time spatial and thermal monitoring enables the
treatment safer and more accurate. Identifying target
nerve is not trivial and the outcome is highly technique-
dependent in radiofrequency [25]. MRgFUS treatment is
not a technique-dependent procedure and low inter-
operator variability is expected. MRgFUS treatment does
not cause widespread hypoesthesia which often observed
in radiofrequency treatment [25], because MRgFUS
treats most peripheral zone of the sensory nerve. On the
other hand, there are some obvious disadvantages of
MRgFUS. Enormous initial cost of the treatment is most
critical. In addition, patients of contraindications for MRI
cannot undergo the treatment. Required time for the set
up and treatment is also longer than radiofrequency.
This study has some limitations. First, the most im-
portant weakness is that it was a case series including
small number of patients without control group. Hence,
it is difficult to be sure that there were no placebo ef-
fects. However, 75% of patients showed successful pain
relief along with significant increase of PPTs. Although
further study with blinded and randomized controlled
trial is required for constructing evidence, our initial re-
sults suggested the safety and efficacy of the treatment.
Second, the inclusion was restricted most severe medial
knee OA because this is a pilot study so that the patients
should be salvaged by TKA conversion. Based on thisstudy and the mechanism of pain relief, medial OA in
earlier stage or lateral OA might possibly become a can-
didate for the treatment. Third, this study did not have a
long follow-up period. Two patients underwent total
knee arthroplasty and one non-responder dropped out
one month after the treatment. Long-term effectiveness
of MRgFUS treatment including ADL and QOL assess-
ment should also be carried out in a continuing study.
Conclusion
MRgFUS treatment had a potential of rapid and long-
lasting pain alleviation without adverse side effects. Sig-
nificant increase of PPTs on treated area showed suc-
cessful denervation effect on the nociceptive nerve
terminals. MRgFUS is a promising and innovative pro-
cedure for noninvasive pain management of knee OA.
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